Abstract:
Provided are a novel transition metal complex where a monocyclopentadienyl ligand to which an amido group is introduced is coordinated, a catalyst composition including the same, and an olefin polymer using the catalyst composition. The transition metal complex has a pentagon ring structure having an amido group connected by a phenylene bridge in which a stable bond is formed in the vicinity of a metal site, and thus, a sterically hindered monomer can easily approach the transition metal complex. By using a catalyst composition including the transition metal complex, a linear low density polyolefin copolymer having a high molecular weight and a very low density polyolefin copolymer having a density of 0.910 g/cc or less can be produced in a polymerization of monomers having large steric hindrance. Further, the reactivity for the olefin monomer having large steric hindrance is excellent.
Abstract:
Provided are a novel transition metal complex where a monocyclopentadienyl ligand to which an amido group is introduced is coordinated, a catalyst composition including the same, and an olefin polymer using the catalyst composition.The transition metal complex has a pentagon ring structure having an amido group connected by a phenylene bridge in which a stable bond is formed in the vicinity of a metal site, and thus, a sterically hindered monomer can easily approach the transition metal complex. By using a catalyst composition including the transition metal complex, a linear low density polyolefin copolymer having a high molecular weight and a very low density polyolefin copolymer having a density of 0.910 g/cc or less can be produced in a polymerization of monomers having large steric hindrance. Further, the reactivity for the olefin monomer having large steric hindrance is excellent.
Abstract:
Provided is catalyst composition including a transition metal complex precatalyst represented by Formula 1; a first cocatalyst represented by Formula 2 which is an alkylaluminum compound; and a second cocatalyst represented by Formula 3 which is a salt compound comprising a Bronsted acid cation and a noncoordinating, compatible anion. Here, R1, R2, R3, R4, E, Q1, Q2 and M are defined in the specification. Al(R6)3 Formula 2 Here, R6 is defined in the specification. [L-H]+[ZA4]− Formula 3 Here, L, [L-H]+, Z and A are defined in the specification. A catalyst composition including binuclear transition metal complexes, an alkylaluminum compound, and a salt compound including a Bronsted acid cation, and a noncoordinating, compatible anion, and a method of preparing the catalyst composition are provided.
Abstract:
The present invention provides a method of wireless communication over a communication link including at least one carrier that comprises a plurality of sub-carriers. The method includes modifying at least one frequency of at least one uplink sub-carrier in response to a signal indicating a modification of the frequency.
Abstract:
Provided are a novel transition metal complex where a monocyclopentadienyl ligand to which an amido group is introduced is coordinated, a catalyst composition including the same, and an olefin polymer using the catalyst composition.The transition metal complex has a pentagon ring structure having an amido group connected by a phenylene bridge in which a stable bond is formed in the vicinity of a metal site, and thus, a sterically hindered monomer can easily approach the transition metal complex. By using a catalyst composition including the transition metal complex, a linear low density polyolefin copolymer having a high molecular weight and a very low density polyolefin copolymer having a density of 0.910 g/cc or less can be produced in a polymerization of monomers having large steric hindrance. Further, the reactivity for the olefin monomer having large steric hindrance is excellent.
Abstract:
The present invention relates to a novel arylsulfonylimidazolone derivative represented by the following formula (I) which shows a superior antineoplastic activity in contrast to the known sulfonylurea antitumor agents as well as little side effect: ##STR1## and its pharmaceutically acceptable salt and stereoisomer, in which ----, R.sub.1, and R.sub.2 are as defined in the specification.
Abstract translation:本发明涉及与已知的磺酰脲类抗肿瘤剂相比具有优异的抗肿瘤活性以及其药学上可接受的盐和立体异构体的下式(I)所示的新型芳基磺酰基咪唑啉酮衍生物,其中+ E ,非+ EE,R1和R2如说明书中所定义。